Home | Sitemap | Submit Content | Contact Us   
imageHome : Latest News : ZymoGenetics Announces Special Protocol Assessment for Atacicept in ...

ZymoGenetics Announces Special Protocol Assessment for Atacicept in ...

  • email Email to a friend
  • print Print version

Did you enjoy this article?

(total 0 votes)
Try our own cheap Booking Service139 times read : Adjust font size: Decrease font Enlarge font
image

MSN MoneyCentral - ZymoGenetics and Merck Serono, an affiliate of Merck KGaA, Darmstadt, Germany, are developing atacicept (formerly referred to as TACI-Ig) for the treatment of autoimmune diseases and B-cell malignancies. Atacicept contains the soluble TACI ...

Read this article...



Post your comment comment Comments (0 posted)

copyright